Identification of ZYG11A as a candidate IGF1-dependent proto-oncogene in endometrial cancer
Metrics: PDF 353 views | Full Text 523 views | ?
Laris Achlaug1, Rive Sarfstein1, Karthik Nagaraj1, Lena Lapkina-Gendler1, Ilan Bruchim2, Manisha Dixit3, Zvi Laron4, Shoshana Yakar3 and Haim Werner1,5
1 Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
2 Gynecologic Oncology Division, Hillel Yaffe Medical Center, Affiliated with the Technion Institute of Technology, Haifa, Hadera 38100, Israel
3 David B. Kriser Dental Center, Department of Basic Science and Craniofacial Biology, New York University College of Dentistry, New York, NY 10010, USA
4 Endocrine and Diabetes Research Unit, Schneider Children’s Medical Center, Petah Tikva 49292, Israel
5 Yoran Institute for Human Genome Research, Tel Aviv University, Tel Aviv 69978, Israel
Keywords: insulin-like growth factor-1 (IGF1); IGF1 receptor; ZYG11A; p53; endometrial cancer
Received: May 16, 2019 Accepted: June 19, 2019 Published: July 09, 2019
The insulin-like growth factors (IGF) have a key role in the development of gynecological cancers, including endometrial tumors. Uterine serous carcinoma (USC) constitutes a defined histological category among endometrial cancers. Laron syndrome (LS) is a genetic type of dwarfism that results from mutation of the growth hormone receptor (GHR) gene, and is the best characterized entity under the spectrum of the congenital IGF1 deficiencies. Epidemiological studies have shown that LS patients are protected from cancer development. Recent genome-wide association studies conducted on LS-derived lymphoblastoid cells led to the identification of a series of metabolic genes whose over-representation in this condition might be linked to cancer protection. Our analyses led to the identification of ZYG11A, a potential cell cycle regulator, as a new downstream target for IGF1 action. The aim of the present paper was to investigate the regulation of ZYG11A gene expression by IGF1 and insulin in endometrial cancer cell lines and to assess the impact of tumor suppressor p53 on ZYG11A expression and biological action. Using USC-derived cell lines expressing a wild type or a mutant p53 gene, we demonstrate that IGF1 inhibited ZYG11A mRNA and protein levels in cells containing a wild type p53. On the other hand, IGF1 potently stimulated ZYG11A expression in mutant p53-expressing cells. Data presented here links the IGF1 and p53 signaling pathways with ZYG11A action. The clinical implications of the present study in endometrial and other types of cancer must be further investigated.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.